Clinical update on opportunistic infections in transplantation: Introduction

American Journal of Health-System Pharmacy

Volumn 62, Issue SUPPL. 1, 2005, Pages

  Baillie, G Mark ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ANTIVIRUS AGENT; GANCICLOVIR; VALGANCICLOVIR;

CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS INFECTION; DRUG BIOAVAILABILITY; DRUG TOLERABILITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITALIZATION; HUMAN; MORBIDITY; MORTALITY; MYCOSIS; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR;

EID: 17444421864     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (7)

1. Das A. Cytomegalovirus infection in solid organ transplantation: economic implications. Pharmacoeconomics. 2003; 21:467-75.
2. Henderson R, Carlin D, Kohlhase K et al. Multicenter US study of hospital resource utilization associated with cytomegalovirus-related readmission of renal and heart transplant patients. Transpl Infect Dis. 2001; 3(suppl 2):57-9.
3. Wilson LS, Reyes CM, Stolpman M et al. The direct cost and incidence of systemic fungal infections. Value Health. 2002; 5:26-34.
4. Paya CV. Economic impact of cytomegalovirus in solid organ transplantation. Transpl Infect Dis. 2001; 3(suppl 2):14-9.
5. Kim WR, Badley AD, Wiesner RH et al. The economic impact of cytomegalovirus infection after liver transplantation. Transplantation. 2000; 69:357-61.
6. Somerville KT. Cost advantages of oral drug therapy for managing cytomegalovirus disease. Am J Health-Syst Pharm. 2003; 60(suppl 8):S9-S12.
7. Persson U, Tennvall GR, Andersson S et al. Cost-effectiveness analysis of treatment with liposomal amphotericin B versus conventional amphotericin B in organ or bone marrow transplant recipients with systemic mycoses. Pharmacoeconotnics. 1992; 2:500-8.